GlobeNewswire: Amphastar Pharmaceuticals, Inc. Contains the last 10 of 125 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T09:01:51ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2021/06/15/2247733/0/en/Amphastar-Pharmaceuticals-to-Present-at-the-Raymond-James-Human-Health-Innovation-Conference.html?f=22&fvtc=4&fvtv=22339Amphastar Pharmaceuticals to Present at the Raymond James Human Health Innovation Conference2021-06-15T20:05:00Z<![CDATA[RANCHO CUCAMONGA, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communications, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive V.P. Corporate Administration Center and Sales & Marketing, will be presenting at the Human Health Innovation Conference on Tuesday, June 22, 2021, at 2:00 pm Eastern time.]]>https://www.globenewswire.com/news-release/2021/05/27/2237165/0/en/Amphastar-Pharmaceuticals-to-Present-at-the-Jefferies-Virtual-Healthcare-Conference.html?f=22&fvtc=4&fvtv=22339Amphastar Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference2021-05-27T10:00:00Z<![CDATA[RANCHO CUCAMONGA, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communications, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive V.P. Corporate Administration Center and Sales & Marketing, will participate in an Analyst-Moderated fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 2:30 pm Eastern time.]]>https://www.globenewswire.com/news-release/2021/05/07/2225782/0/en/Amphastar-Announces-Buyback-of-26-of-the-Equity-in-its-ANP-Subsidiary-and-Spin-off-its-Hanxin-Subsidiary.html?f=22&fvtc=4&fvtv=22339Amphastar Announces Buyback of 26% of the Equity in its ANP Subsidiary and Spin-off its Hanxin Subsidiary2021-05-07T20:05:00Z<![CDATA[RANCHO CUCAMONGA, Calif., May 07, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced the restructuring of its Chinese subsidiaries, primarily Amphastar Nanjing Pharmaceuticals Inc. (“ANP”). As part of the restructuring, Amphastar will buyback 26% of ANP’s equity currently held by third parties. In addition, ANP will spin-off its Chinese subsidiary, Nanjing Hanxin Pharmaceutical Technology Co., Ltd. and Hanxin’s subsidiaries (collectively, “Hanxin”). The restructuring is subject to regulatory approval, and the total cash payment by Amphastar for this restructuring will be approximately $29 million.]]>https://www.globenewswire.com/news-release/2021/05/06/2225007/0/en/Amphastar-Pharmaceuticals-Reports-Financial-Results-for-the-Three-Months-Ended-March-31-2021.html?f=22&fvtc=4&fvtv=22339Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 20212021-05-06T20:05:00Z<![CDATA[Reports Net Revenues of $103.0 Million for the Three Months Ended March 31, 2021]]>https://www.globenewswire.com/news-release/2021/05/03/2221160/0/en/Amphastar-Pharmaceuticals-Receives-FDA-Approval-for-Morphine-Sulfate-Injection.html?f=22&fvtc=4&fvtv=22339Amphastar Pharmaceuticals Receives FDA Approval for Morphine Sulfate Injection2021-05-03T10:00:00Z<![CDATA[RANCHO CUCAMONGA, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) approved the Company’s Abbreviated New Drug Application (“ANDA”) for Morphine Sulfate injection 1mg/mL in the 30mL Pump-Jet® Prefilled Syringe System. It is indicated for the management of pain severe enough to require use of an opioid analgesic by Patient-Controlled Analgesia (PCA), only for use with a compatible Alaris® infusion device, and for which alternative treatments are inadequate. For the past 30 years, the company has sold and marketed the product under the “grandfather” exception to the FDA’s “Prescription Drug Wrap-Up” program. Net revenues for the Company’s Morphine injection for the year ended December 31, 2020, were $2.3 million.]]>https://www.globenewswire.com/news-release/2021/04/29/2219453/0/en/Amphastar-Pharmaceuticals-to-Release-First-Quarter-Earnings-and-Hold-Conference-Call-on-May-6th-2021.html?f=22&fvtc=4&fvtv=22339Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 6th, 20212021-04-29T10:00:00Z<![CDATA[RANCHO CUCAMONGA, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its first quarter of 2021 ended March 31, 2021, after the market closes on Thursday, May 6th, 2021, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.]]>https://www.globenewswire.com/news-release/2021/04/06/2205388/0/en/Amphastar-Pharmaceuticals-to-Present-at-the-20th-Annual-Needham-Virtual-Healthcare-Conference.html?f=22&fvtc=4&fvtv=22339Amphastar Pharmaceuticals to Present at the 20th Annual Needham Virtual Healthcare Conference2021-04-06T20:05:00Z<![CDATA[RANCHO CUCAMONGA, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, V.P of Corporate Communications and HR, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive V.P. Corporate Administration Center and Sales & Marketing, will participate in an Analyst-Moderated fireside chat at the Needham Virtual Healthcare Conference on Tuesday, April 13, 2021 at 3:45 pm Eastern time.]]>https://www.globenewswire.com/news-release/2021/03/29/2200548/0/en/Amphastar-Pharmaceuticals-Receives-FDA-Approval-for-Dextrose-Injection.html?f=22&fvtc=4&fvtv=22339Amphastar Pharmaceuticals Receives FDA Approval for Dextrose Injection2021-03-29T10:00:00Z<![CDATA[RANCHO CUCAMONGA, Calif., March 29, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) approved the Company’s Abbreviated New Drug Application (“ANDA”) for Dextrose injection 50% in the 50 mL Luer-Jet® Prefilled Syringe System. For the past 40 years, the company has sold and marketed the product under the “grandfather” exception to the FDA’s “Prescription Drug Wrap-Up” program. Net revenues for the Company’s Dextrose injection for the year ended December 31, 2020, were $7.6 million.]]>https://www.globenewswire.com/news-release/2021/03/15/2193153/0/en/Amphastar-Pharmaceuticals-Reports-Financial-Results-for-the-Three-Months-and-Full-Year-Ended-December-31-2020.html?f=22&fvtc=4&fvtv=22339Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 20202021-03-15T20:05:00Z<![CDATA[Reports Net Revenues of $95.9 Million for the Three Months Ended December 31, 2020 Reports Net Revenues of $95.9 Million for the Three Months Ended December 31, 2020]]>https://www.globenewswire.com/news-release/2021/03/08/2189097/0/en/Amphastar-Pharmaceuticals-to-Release-Fourth-Quarter-Earnings-and-Hold-Conference-Call-on-March-15th-2021.html?f=22&fvtc=4&fvtv=22339Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 15th, 20212021-03-08T22:39:10Z<![CDATA[RANCHO CUCAMONGA, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its fourth quarter of 2020 ended December 31, 2020, after the market closes on Monday, March 15th, 2021, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.]]>